Early Findings From Medicare's End-Stage Renal Disease Treatment Choices Model.
作者信息
Tummalapalli Sri Lekha, Navathe Amol S, Ibrahim Said A
机构信息
Division of Healthcare Delivery Science and Innovation, Department of Population Health Sciences and Division of Nephrology and Hypertension, Department of Medicine, Weill Cornell Medicine, New York, New York.
Department of Medical Ethics and Health Policy, University of Pennsylvania, Philadelphia.
出版信息
JAMA Health Forum. 2022 Oct 7;3(10):e223500. doi: 10.1001/jamahealthforum.2022.3500.
Abstract
摘要
相似文献
1
Early Findings From Medicare's End-Stage Renal Disease Treatment Choices Model.医疗保险终末期肾病治疗选择模型的早期研究结果。
JAMA Health Forum. 2022 Oct 7;3(10):e223500. doi: 10.1001/jamahealthforum.2022.3500.
2
Are we ready for revisions in Medicare's conditions of coverage for ESRD suppliers?我们是否准备好对医疗保险中终末期肾病供应商的承保条件进行修订？
J Ren Nutr. 2003 Jan;13(1):1. doi: 10.1053/jren.2003.50013.
3
Medicare's ESRD program, Part 2: Transplantation.医疗保险的终末期肾病项目，第2部分：移植
Physician Exec. 1989 May-Jun;15(3):31-3.
4
Special treatment--the story of Medicare's ESRD entitlement.特殊待遇——医疗保险的终末期肾病权益历程
N Engl J Med. 2011 Feb 17;364(7):596-8. doi: 10.1056/NEJMp1014193.
5
Validation of erythropoietin use data on Medicare's End-Stage Renal Disease Medical Evidence Report.医疗保险终末期肾病医疗证据报告中促红细胞生成素使用数据的验证
J Rehabil Res Dev. 2010;47(8):751-62. doi: 10.1682/jrrd.2009.08.0108.
6
Physicians and Medicare's future.医生与医疗保险的未来。
Nephrol News Issues. 2013 Sep;27(10):8, 11.
7
Medicare's end-stage renal disease program: current status and future prospects.医疗保险的终末期肾病项目：现状与未来展望。
Health Aff (Millwood). 1999 Jan-Feb;18(1):161-79. doi: 10.1377/hlthaff.18.1.161.
8
Bundled payment for ESRD--including ESAs in Medicare's dialysis package.终末期肾病的捆绑支付——医疗保险透析套餐中包括促红细胞生成素类似物。
N Engl J Med. 2011 Feb 17;364(7):593-5. doi: 10.1056/NEJMp1014187.
9
Mortality rates among dialysis patients in Medicare's End-Stage Renal Disease Program.医疗保险终末期肾病项目中透析患者的死亡率
Am J Kidney Dis. 1990 May;15(5):414-21. doi: 10.1016/s0272-6386(12)70359-1.
10
Validation of the cause of renal failure of patients in the Medicare end-stage renal disease program.医疗保险终末期肾病项目中患者肾衰竭病因的验证
Am J Kidney Dis. 1991 Sep;18(3):375-8. doi: 10.1016/s0272-6386(12)80098-9.
引用本文的文献
1
Association of Primary Care Continuity With Home Dialysis, Transplantation, and Utilization of Medical Services for Patients Starting Hemodialysis.初级保健连续性与血液透析起始患者的家庭透析、移植及医疗服务利用之间的关联
Kidney Med. 2025 Apr 19;7(6):101015. doi: 10.1016/j.xkme.2025.101015. eCollection 2025 Jun.
2
Neighborhood Built Environment and Home Dialysis Utilization: Varying Patterns by Urbanicity-Dependent Patterns and Implications for Policy.邻里建成环境与家庭透析利用情况：依城市化程度而异的模式及其对政策的影响
Am J Kidney Dis. 2025 Jun;85(6):737-744. doi: 10.1053/j.ajkd.2025.01.015. Epub 2025 Mar 11.
3
Early Effects of the ESRD Treatment Choices Model on Kidney Transplant Waitlist Additions.终末期肾病治疗选择模型对肾脏移植等待名单增加的早期影响。
Clin J Am Soc Nephrol. 2025 Jan 1;20(1):124-135. doi: 10.2215/CJN.0000000000000571. Epub 2024 Oct 16.
本文引用的文献
1
Financial Incentives to Facilities and Clinicians Treating Patients With End-stage Kidney Disease and Use of Home Dialysis: A Randomized Clinical Trial.为治疗终末期肾病患者并使用居家透析的医疗机构和临床医生提供经济激励：一项随机临床试验。
JAMA Health Forum. 2022 Oct 7;3(10):e223503. doi: 10.1001/jamahealthforum.2022.3503.
2
Treatment Patterns and Characteristics of Dialysis Facilities Randomly Assigned to the Medicare End-Stage Renal Disease Treatment Choices Model.随机分配到医疗保险终末期肾脏疾病治疗选择模型的透析机构的治疗模式和特征。
JAMA Netw Open. 2022 Aug 1;5(8):e2225516. doi: 10.1001/jamanetworkopen.2022.25516.
3
Medicare's Specialty-Oriented Accountable Care Organization: First-Year Results For People With End-Stage Renal Disease.医疗保险专科导向型责任医疗组织：终末期肾病患者第一年的结果。
Health Aff (Millwood). 2022 Jun;41(6):893-900. doi: 10.1377/hlthaff.2021.01856.
4
Medicare Bundled Payment Policy on Anemia Care, Major Adverse Cardiovascular Events, and Mortality among Adults Undergoing Hemodialysis.医疗保险捆绑支付政策对接受血液透析成年人的贫血护理、主要不良心血管事件和死亡率的影响。
Clin J Am Soc Nephrol. 2022 Jun;17(6):851-860. doi: 10.2215/CJN.14361121. Epub 2022 May 19.
5
Cost Barriers to More Widespread Use of Peritoneal Dialysis in the United States.美国腹膜透析更广泛应用的成本障碍。
J Am Soc Nephrol. 2022 Jun;33(6):1063-1072. doi: 10.1681/ASN.2021060854. Epub 2022 Mar 21.
6
Changes in Treatment of Patients with Incident ESKD during the Novel Coronavirus Disease 2019 Pandemic.新型冠状病毒病 2019 大流行期间新发终末期肾病患者的治疗变化。
J Am Soc Nephrol. 2021 Nov;32(11):2948-2957. doi: 10.1681/ASN.2021040579. Epub 2021 Sep 17.
7
The Nephrology Nursing Shortage: Insights From a Pandemic.肾脏病护理短缺：大流行带来的见解
Am J Kidney Dis. 2022 Jan;79(1):113-116. doi: 10.1053/j.ajkd.2021.07.007. Epub 2021 Aug 16.
8
Policies to Support Home Dialysis Patients: Patients Need Help Too.支持家庭透析患者的政策：患者也需要帮助。
Am J Kidney Dis. 2022 May;79(5):746-749. doi: 10.1053/j.ajkd.2021.06.029. Epub 2021 Aug 11.
9
Socioeconomic Factors and Racial and Ethnic Differences in the Initiation of Home Dialysis.家庭透析起始阶段的社会经济因素以及种族和民族差异
Kidney Med. 2020 Feb 11;2(2):105-115. doi: 10.1016/j.xkme.2019.11.006. eCollection 2020 Mar-Apr.
10
Comparisons of quality of life between patients underwent peritoneal dialysis and hemodialysis: a systematic review and meta-analysis.比较腹膜透析和血液透析患者的生活质量：系统评价和荟萃分析。
Health Qual Life Outcomes. 2020 Jun 18;18(1):191. doi: 10.1186/s12955-020-01449-2.
Zotero 插件